Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Medicine and Dentistry
Neoplasm
100%
Breast Cancer
76%
Biopsy
45%
Malignant Neoplasm
44%
Salivary Gland
40%
Sjoegren Syndrome
34%
Mouth Squamous Cell Carcinoma
31%
Immunohistochemistry
28%
Parotid Gland
28%
Head and Neck Squamous Cell Carcinoma
27%
Neck
25%
Diagnosis
23%
Recurrent Disease
23%
Head and Neck Cancer
23%
Estrogen Receptor
22%
Surgical Margin
21%
Metastatic Breast Cancer
21%
Gamma Urogastrone
20%
Metastatic Carcinoma
19%
Histopathology
19%
Oral Cancer
19%
Molecular Imaging
18%
Disease
17%
Epidermal Growth Factor Receptor 2
17%
Intraductal Carcinoma
16%
Biological Marker
15%
Epidermal Growth Factor Receptor
15%
Germinal Center
14%
Image Analysis
14%
Macrophage
14%
Hazard Ratio
13%
Positron Emission Tomography
13%
Systematic Review
12%
B Cell
12%
Receptor Expression
12%
Cetuximab
12%
Lymph Node Metastasis
11%
Lymph Node
11%
Gland Tissue
11%
Triple Negative Breast Cancer
11%
Salivary Gland Biopsy
10%
Specific Tumor
10%
Radioactive Tracer
10%
Laryngeal Cancer
10%
Overall Survival
10%
Cancer Incidence
10%
Imaging Agent
10%
Radiation Therapy
9%
Breast Carcinoma
9%
Carcinoma
9%
Keyphrases
Primary Sjögren's Syndrome
26%
Primary Sjgren's Syndrome
24%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
18%
Breast Cancer
15%
Human Epidermal Growth Factor Receptor 2 (HER2)
15%
Parotid Gland
14%
Germinal Center
14%
Confidence Interval
13%
Head-and-neck Cancer
13%
Digital Image Analysis
12%
Metastasis
11%
Immunohistochemistry
11%
Parotid
11%
Epidermal Growth Factor Receptor
11%
Minor Salivary Gland Biopsy
10%
Hazard Ratio
10%
Metastatic Breast Cancer
10%
Abatacept
9%
Salivary Gland
9%
Oral Tongue Squamous Cell Carcinoma (OTSCC)
9%
Netherlands
9%
Tumor
8%
Primary Tumor
8%
Cancer Risk
8%
Overall Survival
8%
Histopathological Features
7%
Molecular Imaging
7%
Tumor Characteristics
7%
Laryngeal Squamous Cell Carcinoma
7%
Newly Diagnosed
7%
18F-FES PET
7%
Programmed Death-ligand 1 (PD-L1)
7%
High Risk
7%
Imaging Target
7%
Inter-laboratory Variation
6%
Clinical Outcomes
6%
Ductal Carcinoma in Situ
6%
Tumor Microenvironment
6%
Local Recurrence
6%
Estrogen Receptor Status
6%
Human Epidermal Growth Factor Receptor 2-negative
6%
Clinical Data
6%
Germline Pathogenic Variant
6%
Risk-reducing Salpingo-oophorectomy
6%
Invasive Ductal Breast Carcinoma
6%
GPNMB
6%
CGAS-STING
6%
Locally Advanced
6%
DNA Methyltransferase 1 (DNMT1)
6%
Longitudinal Change
6%
